Title Page

Contents

Abstract (English) 8

Ⅰ. Introduction 10

Ⅱ. Material & Methods 13

1. Cells and reagents 13

2. Transfections 13

3. Quantitative Real-Time PCR (qRT-PCR) 14

4. Western Blotting (WB) 15

5. Luciferase Reporter Assays 16

6. Cell Viability 16

7. Drug Treatment Assays 17

8. Scratch Wound Healing Assays 17

9. Invasion Assays 18

10. Colony Formation Assays 18

11. In Vivo Studies 19

12. Statistics 20

Ⅲ. Results 21

1. DDX53 positively correlates with EC Metastasis 21

2. DDX53 increases the EC progression. 23

3. DDX53 Upregulates Chemoresistance and Mesenchymal Markers in EC Cells 25

4. Regulation of DDX53 expression by miR-429 through direct targeting of its 3'-UTR 27

5. MiR-429 regulates EC metastasis and proliferation by targeting DDX53 29

6. Downregulated miR-429 contributes to EMT and increased anti-cancer sensitivity in EC cells 32

7. The miR-429/DDX53 axis regulates in vivo EC tumor progression 34

Ⅳ. Discussion 36

Ⅴ. Conclusion 40

Ⅵ. Reference 41

Ⅶ. Abstract (Korean) 45

Figure 1. DDX53 regulation contributes to EC metastasis. 22

Figure 2. DDX53 increase the EC progression. 24

Figure 3. DDX53 Upregulates Chemoresistance and Mesenchymal Markers in EC Cells. 26

Figure 4. DDX53 is targeted by MiR-429. 28

Figure 5. MiR-429 regulates EMT in EC cells. 31

Figure 6. MiR-429 suppresses mesenchymal markers and chemoresistance. 33

Figure 7. In vivo miR-429/DDX53 axis therapeutic effects. 35